TG Therapeutics expands credit facility to $200M, extends maturity to 2026

TG THERAPEUTICS, INC.

Loan increased from $60M to $200M; initial $70M drawn, $7.8M used to refinance existing balance.
Maturity extended to Jan 1, 2026; interest-only period extended to Feb 1, 2025 (extendable to Aug 1, 2025).
Interest rate: prime + 2.15% (floor 5.40%); warrants issued for 115,042 shares at $17.95, 7-year term.
Financial covenants: minimum cash from Oct 15, 2022; market cap/cash covenants from July 1, 2023 if drawn >$70M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.